HOME CAREERS CONTACT US KOREAN ENGLISH

NEWS

  1. HOME
  2. MEDIA
  3. NEWS

Press Releases

April 18, 2024NeoImmuneTech’s NT-I7 in Combination with Chemotherapy Shows Efficacy in Colorectal Cancer at AACR Meeting
April 04, 2024QUARTERLY UPDATE (Q1 2024)
April 03, 2024NeoImmuneTech Appoints Dr. Luke Oh, Ph.D. as New Chief Executive Officer
January 30, 2024FDA Grants Orphan Drug Designation (ODD) Status to NeoImmuneTech’s NT-I7 for Advanced Pancreatic Cancer Treatment
January 29, 2024Phase II Study Expansion Investigating NeoimmuneTech’s NT-I7 in Head and Neck Cancer
January 15, 2024NeoImmuneTech Welcomes a New President for its development and business
January 04, 2024QUARTERLY UPDATE (Q4 2023)
December 12, 2023NeoImmuneTech and Imugene enter into strategic research collaboration to improve cancer treatments
November 20, 2023FDA Grants Orphan Drug Designation to NeoImmuneTech’s NT-I7 for the Treatment of Acute Radiation Syndrome
October 26, 2023QUARTERLY UPDATE (Q3 2023)
October 04, 2023NeoImmuneTech to Present New Advances on NT-I7 (efineptakin alfa) at 2023 SITC Annual Meeting
July 26, 2023NeoImmuneTech Welcomes Two New Members to its Scientific Advisory Board
July 05, 2023QUARTERLY UPDATE (Q2 2023)
June 20, 2023NeoImmuneTech and NIAID Embark on a Collaborative Study to Explore New Treatment for Acute Radiation Syndrome (ARS)
April 05, 2023QUARTERLY UPDATE (Q1 2023)
February 07, 2023First Patient Dosed in Phase II Study of NeoImmuneTech’s NT-I7 plus Pembrolizumab in Recurrent Glioblastoma
January 06, 2023QUARTERLY UPDATE (Q4 2022)
January 03, 2023NeoImmuneTech to Partner with U.S. National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) for Drug Development in Acute Radiation Syndrome (ARS)
December 19, 2022Pharmaphorum highlights NeoImmuneTech
December 15, 2022NeoImmuneTech to Present at 2023 Biotech Showcase
November 14, 2022New evidence of NeoImmuneTech’s NT-I7 clinical efficacy in combination with pembrolizumab in relapsed/refractory (r/r) gastrointestinal tumors
November 04, 2022NeoImmuneTech to Present First Data on NT-I7 (efineptakin alfa) in Combination with CAR-T tisagenlecleucel, at 2022 ASH Annual Meeting
October 11, 2022NeoImmuneTech Joins the United Nations Global Compact
October 06, 2022NeoImmuneTech to Present New Advances on NT-I7 (efineptakin alfa) at 2022 SITC Annual Meeting
October 04, 2022QUARTERLY UPDATE (Q3 2022)
September 13, 2022NeoImmuneTech’s NT-I7 Creates a More Immunogenic Tumor Microenvironment when Associated with Pembrolizumab
August 08, 2022NeoImmuneTech Welcomes New Members to its Scientific Advisory Board
July 26, 2022NeoImmuneTech to Present at Cytokine-Based Drug Development Summit
July 13, 2022FDA Grants Orphan Drug Designation (ODD) Status to NeoImmuneTech’s NT-I7 for the treatment of Glioblastoma Multiforme
July 12, 2022QUARTERLY UPDATE (2Q 2022)
July 04, 2022Interest of Combining NeoImmuneTech’s Lead Asset NT-I7 (efineptakin alfa) with Pembrolizumab keeps Growing
June 30, 2022NeoImmuneTech to Display its Environmental, Social, and Governance Activities on its Corporate Website
June 15, 2022A Study in Nature Communications Reports that NeoImmuneTech\\\'s NT-I7 Enhances CAR-T Cell Expansion, Persistence and Anti-tumor Activity
June 13, 2022NeoImmuneTech to Present at Upcoming BIO International Convention
June 07, 2022NeoImmuneTech’s Lead Asset NT-I7 (efineptakin alfa) Shows Preliminary Anticancer Activity in Combination with Check-Point Inhibitors
May 19, 2022NeoImmuneTech to Present at Immuno-Oncology Summit Europe 2022
May 11, 2022NeoImmuneTech Received U.S. FDA Clearance of IND Application for Phase II Study of NT-I7 and Pembrolizumab in Recurrent Glioblastoma
April 28, 2022NeoImmuneTech to Show Significant Advances on NT-I7 (efineptakin alfa) at 2022 ASCO Annual Meeting
April 14, 2022NeoImmuneTech Demonstrates NT-I7’s Broad Combination Potential with Immune Checkpoint Inhibitors and Immunocytokine at AACR 2022
March 16, 2022NeoImmuneTech to Celebrate First Year of Trading at KOSDAQ
March 10, 2022NeoImmuneTech to Present Two Posters at American Association for Cancer Research Annual Meeting
February 09, 2022NeoImmuneTech to Present at Upcoming Business Conferences
February 07, 2022NeoImmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) with PD-L1 checkpoint inhibitor in High-Risk Skin Cancers
January 24, 2022Preclinical Data on NT-I7 Published in Clinical Cancer Research
January 05, 2022NeoImmuneTech to Present at 2022 Biotech Showcase at J.P. Morgan Healthcare Conference
November 22, 2021NeoImmuneTech Presents Phase 1 Study Data at Society for Neuro-Oncology Annual Meeting
November 16, 2021NeoImmuneTech Presents Data in Three Posters at Society for Immunotherapy of Cancer Annual Meeting
November 08, 2021NeoImmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) in combination with PD-L1 checkpoint inhibitor in Frontline Locally Advanced or Metastatic Non-Small Cell Lung Cancer
October 13, 2021NeoImmuneTech Announces First Patient Dosed in Phase 1b Study of NT-I7 (efineptakin alfa) and Kymriah® (tisagenlecleucel) in Relapsed/Refractory Large B-Cell Lymphoma
October 05, 2021NeoImmuneTech to Present Three Posters at Society for Immunotherapy of Cancer Annual Meeting
September 03, 2021NeoImmuneTech to Present at Society for Neuro-Oncology Annual Meeting
August 25, 2021NeoImmuneTech Appoints Jean Fan, M.D., as Chief Clinical Officer
July 26, 2021NeoImmuneTech Receives U.S. FDA IND Clearance for Phase 1 Study of NT-I7 (efineptakin alfa) for the Treatment of Kaposi Sarcoma in Patients With or Without HIV Infection
June 08, 2021NeoImmuneTech Trial Data Presented at American Society of Clinical Oncology Annual Meeting
June 08, 2021 NeoImmuneTech Announces First Clinical Trial Application Authorization Received in the EU for its Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo® (nivolumab)
May 25, 2021NeoImmuneTech Announces First Patient Dosed in the Pilot Study of NT-I7 (efineptakin alfa) in Progressive Multifocal Leukoencephalopathy
May 20, 2021NeoImmuneTech to Present Two Posters at American Society of Clinical Oncology Annual Meeting
March 30, 2021NeoImmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) in Patients with High Grade Glioma
March 23, 2021NeoImmuneTech Announces First Patient Dosed in Phase 2a Portion of Basket Study Evaluating NT-I7 (efineptakin alfa) and KEYTRUDA® (pembrolizumab) in Relapsed/Refractory Advanced Solid Tumors
March 16, 2021NeoImmuneTech Announces Closing of Initial Public Offering
March 01, 2021NeoImmuneTech Appoints Byung Ha Lee, Ph.D., as Chief Scientific Officer
February 23, 2021NeoImmuneTech Receives U.S. FDA IND Clearance for Pilot Study of NT-I7 (efineptakin alfa) in Progressive Multifocal Leukoencephalopathy
February 16, 2021NeoImmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo® (nivolumab)
December 30, 2020NeoImmuneTech Receives Notice of Approval from the Korea Exchange for Initial Public Offering on the KOSDAQ
November 30, 2020NeoImmuneTech Announces First Patient Dosed in Phase 1 Study of NT-I7 (efineptakin alfa) in Adults with Mild COVID-19
November 16, 2020NeoImmuneTech Receives U.S. FDA IND Clearance for Phase 2 Study of NT-I7 (efineptakin alfa) in combination with PD-L1 checkpoint inhibitor in First-line Non-small Cell Lung Cancer
November 10, 2020NeoImmuneTech to Present at Upcoming Scientific/Medical Conferences
November 10, 2020Genexine and NeoImmuneTech Announce Data Release for their Phase 1b/2 Study of GX-I7/NT-I7 (efineptakin alfa) and KEYTRUDA® (pembrolizumab) in patients with Triple-negative Breast Cancer
October 21, 2020NeoImmuneTech Announces a Second Clinical Collaboration with Roche to Evaluate NT-I7 (efineptakin alfa) in Combination with PD-L1 checkpoint inhibitor in First-line Non-small Cell Lung Cancer
August 24, 2020NeoImmuneTech Receives U.S. FDA IND Clearance for Phase 1b Study of NT-I7 (efineptakin alfa) and Kymriah® (tisagenlecleucel) in Relapsed/Refractory Large B-Cell Lymphoma
July 27, 2020NeoImmuneTech Announces FDA Approval to Proceed with Second Study of NT-I7 (efineptakin alfa) in Adult COVID-19 Patients
July 27, 2020NeoImmuneTech Announces Receipt of IND Clearance to Conduct Window-of-Opportunity Trial of NT-I7 (efineptakin alfa) in Patients with Locally Recurrent Squamous Cell Carcinoma of Head and Neck
July 20, 2020NeoImmuneTech Receives U.S. FDA Clearance of IND Application for Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo® (nivolumab)
July 15, 2020NeoImmuneTech Announces Clearance for Investigational New Drug Application of NT-I7 (efineptakin alfa) in Adults with Mild COVID-19
June 25, 2020NeoImmuneTech Announces First Patient Dosed in Phase 1b/2a Study of NT-I7 (efineptakin alfa) and KEYTRUDA® (pembrolizumab) in Patients with Relapsed/Refractory Advanced Solid Tumors
June 15, 2020NeoImmuneTech Receives FDA Orphan Drug Designation for NT-I7 (efineptakin alfa) for the Treatment of Progressive Multifocal Leukoencephalopathy
April 09, 2020NeoImmuneTech Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate NT-I7 (Hyleukin-7™) in Combination with Nivolumab
March 23, 2020NeoImmuneTech Enters into Exclusive License Agreement with Ubix Therapeutics to Develop Drug Candidates Including T Cell Suppressor Blockade
January 30, 2020NeoImmuneTech Appoints Gene Namgoong as Chief Operating Officer
January 28, 2020NeoImmuneTech Received U.S. FDA Clearance of IND Application for Phase 1b/2a Study of Hyleukin-7™ (NT-I7) and KEYTRUDA® (Pembrolizumab) in Relapsed/Refractory Advanced Solid Tumors
December 11, 2019NeoImmuneTech Announces Clinical Collaboration to Evaluate Hyleukin-7™ (NT-I7) in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
November 13, 2019NeoImmuneTech Announces Formation of Scientific Advisory Board to Support Development of its Immunotherapeutics Portfolio
June 04, 2019NeoImmuneTech Appoints Dr. Samuel Zhang as Chief Business Officer
May 24, 2019NeoImmuneTech Announces that the FDA has Allowed the Center for Cancer Research, National Cancer Institute to Proceed with an Investigational New Drug Application to Initiate a Clinical Trial for Hyleukin-7™ with Vaccines in Elderly Cancer Survivors
April 26, 2019Genexine and NeoImmuneTech Announce Dosing of First Patient in the Combination Trial of Hyleukin-7TM with Merck’s KEYTRUDA® in Triple-Negative Breast Cancer
April 16, 2019FDA Grants Orphan Drug Designation Status to NeoImmuneTech’s Hyleukin-7 for Idiopathic CD4+ Lymphocytopenia Treatment
April 03, 2019NeoImmuneTech, Genexine, SNUH and POSTECH researchers Announce Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2019
January 16, 2019NeoImmuneTech Receives Authorization to Proceed from the FDA for IND Application to Evaluate Hyleukin-7TM in Combination with a PD-L1 Inhibitor in Advanced High-Risk Skin Cancers
December 03, 2018NeoImmuneTech Presents Hyleukin-7TM and Universal CAR-T Combination Therapy Preclinical Data at ASH Annual Meeting
October 29, 2018NeoImmuneTech Announces Initiation of Clinical Trial for Hyleukin-7TM Treatment in Combination with Standard Therapy for Newly Diagnosed Brain Cancer Patients
October 29, 2018NeoImmuneTech Strengthens Senior Management with the Appointment of NgocDeip Le, M.D., Ph.D., as Medical Officer
July 18, 2018Hyleukin-7TM Selected as a Korea Drug Development Fund (KDDF) Project for Combination Trial with Merck’s KEYTRUDA®
June 01, 2018NeoImmuneTech Announces Initiation of Hyleukin-7TM Clinical Development for Cancer Patients in the U.S.
May 02, 2018NeoImmuneTech Announces a Clinical Trial Collaboration with a Global Leading Pharmaceutical Company to Evaluate HyLeukin-7TM in Combination with a PD-L1 Checkpoint Inhibitor in Advanced High-Risk Skin Cancers